All In Biotech

Drug Trial Radar · NCT05487170

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Chaperone-mediated Protein Degrader RNK05047 in Subjects With Advanced Solid Tumors (CHAMP-1)

Last checked: Nov 19, 2026Latest source record: Mar 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Jul 12, 2022

Primary completion

Jun 1, 2025

Study completion Sep 1, 2025

Sponsor

Sponsor type
Industry
First posted
Aug 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous (IV) infusion to subjects with advanced solid tumors, including diffuse large B-cell lymphoma (DLBCL). This is a 2-part study (dose escalation, cohort expansion) with sequential enrollment.

Conditions

  • Advanced Solid Tumor
  • DLBCL

Interventions

  • RNK05047Drug

    RNK05047 is a chaperone-mediated protein degrader administered as IV infusion once weekly for 3 consecutive weeks in a 4-week cycle (no treatment in the fourth week).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Incidence of DLTsTime frame: through 1 cycle/4 weeks
  2. Part 1: Incidence of TEAEsTime frame: through study completion, an average of 1 year
  3. Part 2: Incidence of TEAEsTime frame: through study completion, an average of 1 year
  4. Part 2: Objective response rate (ORR) based on RECIST 1.1/RECIL 2017Time frame: through study completion, an average of 1 year
  5. Part 2: Duration of response (DoR) based on RECIST 1.1/RECIL 2017Time frame: through study completion, an average of 1 year
  6. Part 2: Progression-free Survival (PFS) based on RECIST 1.1/RECIL 2017Time frame: through study completion, an average of 1 year
  7. Part 2: Disease Control Rate (DCR) based on RECIST 1.1/RECIL 2017Time frame: through study completion, an average of 1 year

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Emory University Winship Cancer Institute

    Atlanta, Georgia · Completed

  • Norton Cancer Institute

    Louisville, Kentucky · Completed

  • Weill Cornell - NY Presbyterian Hospital

    New York, New York · Completed

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.